NeuroOne Medical Technologies Corporation NMTC
0.80 USD 0.00 (-0.19%)
Nov 12, 2026, 1:47 PM EST
0.7675 Day range 0.8399
0.75 52-week range 6.12
- YTD
- -82.40%
- 1 year
- -81.80%
News
benzinga.com NeuroOne Medical Technologies Publishes Initial Clinical Results For Its OneRF Trigeminal Nerve Ablation System NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on the surgical diagnosis and treatment of neurological disorders, today
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Lucid Diagnostics (NASDAQ:LUCD) stock moved upwards by 41.9% to $0.46 during Thursday's after-market session. The company's market cap stands at $67.1 million. Aardvark Therapeutics…
benzinga.com NeuroOne Secures First Pharmaceutical Industry Purchase Order For StereoCED Drug Delivery Platform; No Terms Disclosed Major Commercial Milestone Represents Important Step Toward Potential Long-Term Collaborations with Global Pharmaceutical CompaniesEDEN PRAIRIE, Minn., Oct. 22, 2026 (GLOBE NEWSWIRE) -- NeuroOne…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers SCWorx Corp. - Common Stock (NASDAQ:WORX) shares moved upwards by 48.8% to $6.25 during Thursday's after-market session. XORTX Therapeutics (NASDAQ:XRTX) stock increased by 22.7% to $2.27.…
benzinga.com NeuroOne Medical Technologies Reports Preliminary Q4 Sales ~$3.8M , Up 38.4% YoY; Sees FY26 Sales Of ~$10.5M, Up 15.6% YoY; Includes September Purchase Order Of $4.5M NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers AEON Biopharma (AMEX:AEON) stock moved upwards by 8.9% to $0.32 during Thursday's after-market session. The company's market cap stands at $11.5 million. Picard Medical (AMEX:PMI) stock moved…
benzinga.com NeuroOne Completes Three Large-Animal StereoCED Procedures, Including Combined Drug Delivery And Brain Recording; Builds Momentum Toward Planned Launch Of The StereoCED Platform For Human Investigational Clinical Studies Later This Quarter Successful Large-Animal Procedures Build Momentum Toward Planned Launch of the StereoCED™ Platform for Human Investigational Clinical Studies Later This Quarter Related StereoCED™ Revenue Expected to…- benzinga.com Maxim Group Maintains Buy on NeuroOne Medical Tech, Lowers Price Target to $5 Maxim Group analyst Anthony Vendetti maintains NeuroOne Medical Tech (NASDAQ:NMTC) with a Buy and lowers the price target from $13 to $5.
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com NeuroOne Medical Tech Q2 2026 Earnings Call Transcript
benzinga.com NeuroOne Medical Tech Q2 EPS $(0.25) Misses $(0.23) Estimate, Sales $2.391M Miss $2.576M Estimate NeuroOne Medical Tech (NASDAQ:NMTC) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.23) by 8.7 percent. This is a 40.48 percent increase over losses…
benzinga.com Earnings Scheduled For May 12, 2026 - benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com Jones Trading Initiates Coverage On NeuroOne Medical Tech with Buy Rating, Announces Price Target of $1.5 Jones Trading analyst Justin Walsh initiates coverage on NeuroOne Medical Tech (NASDAQ:NMTC) with a Buy rating and announces Price Target of $1.5.
benzinga.com Insights into NeuroOne Medical Tech Q1 Earnings - benzinga.com NeuroOne Medical Tech Q1 EPS $(0.03) Beats $(0.04) Estimate, Sales $2.893M Beat $2.678M Estimate NeuroOne Medical Tech (NASDAQ:NMTC) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.04) by 25 percent. This is a 150 percent decrease over earnings of…
- benzinga.com Earnings Scheduled For February 17, 2026
benzinga.com What to Expect from NeuroOne Medical Tech's Earnings 
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session - benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com NeuroOne Medical Tech Q4 EPS $(0.04), Inline, Sales $2.741M Beat $2.470M Estimate NeuroOne Medical Tech (NASDAQ:NMTC) reported quarterly losses of $(0.04) per share which met the analyst consensus estimate. This is a 63.64 percent increase over losses of $(0.11) per share from the…
benzinga.com NeuroOne Medical Technologies Reports Preliminary FY25 Results Of $9.1M Product Revenue And $6.6M Cash On Hand Preliminary Results On October 6, 2024, the Company reported the following preliminary unaudited fiscal year 2025 financial and operational results: ●Achieved annual total product revenue of- benzinga.com Maxim Group Initiates Coverage On NeuroOne Medical Tech with Buy Rating, Announces Price Target of $3 Maxim Group analyst Anthony Vendetti initiates coverage on NeuroOne Medical Tech (NASDAQ:NMTC) with a Buy rating and announces Price Target of $3.
- benzinga.com NeuroOne Medical Tech Affirms FY2025 Sales Guidance of $8.00M-$10.00M vs $8.71M Est NeuroOne Medical Tech (NASDAQ:NMTC) affirms FY2025 sales outlook from $8.00 million-$10.00 million to $8.00 million-$10.00 million vs $8.71 million estimate.
benzinga.com NeuroOne Medical Tech Q3 EPS $(0.03) Beats $(0.05) Estimate, Sales $1.70M Miss $1.82M Estimate NeuroOne Medical Tech (NASDAQ:NMTC) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.05) by 40 percent. This is a 70 percent increase over losses of…
benzinga.com Earnings Scheduled For August 14, 2025 - benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com NeuroOne Medical Technologies Patient Treated With Patented OneRF Ablation System Surpasses One Year Milestone Of Being Seizure Free Patient Treated with OneRF® Ablation System Previously Experienced up to 10 Seizures a DayEDEN PRAIRIE, Minn., June 23, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation…
- benzinga.com NeuroOne Medical Tech Affirms FY2025 Product Revenue Guidance of $8.00M-$10.00M NeuroOne Medical Tech (NASDAQ:NMTC) affirms FY2025 sales outlook from $8.00 million-$10.00 million to $8.00 million-$10.00 million.
- benzinga.com NeuroOne Medical Tech Q2 EPS $(0.07) Up From $(0.11) YoY, Sales $1.39M Beat $1.27M Estimate NeuroOne Medical Tech (NASDAQ:NMTC) reported quarterly losses of $(0.07) per share. This is a 36.36 percent increase over losses of $(0.11) per share from the same period last year. The company…
- benzinga.com Earnings Scheduled For May 13, 2025
benzinga.com This Okta Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - benzinga.com Ladenburg Thalmann Initiates Coverage On NeuroOne Medical Tech with Buy Rating, Announces Price Target of $1.45 Ladenburg Thalmann analyst Jeff Cohen initiates coverage on NeuroOne Medical Tech (NASDAQ:NMTC) with a Buy rating and announces Price Target of $1.45.
- benzinga.com NeuroOne Medical Technologies Files 510(k) Submission To FDA For Trigeminal Nerve Ablation Earlier Than Anticipated Multi-Contact Probe Provides Alternative to Pharmaceutical and Invasive Surgical TreatmentsSubmission Completed Earlier Than AnticipatedEDEN PRAIRIE, Minn., April 23, 2025 (GLOBE NEWSWIRE) --…
benzinga.com EXCLUSIVE: NeuroOne Submits FDA Marketing Application For OneRF Trigeminal Nerve Ablation System For Facial Pain NeuroOne submits FDA filing early for trigeminal nerve ablation using its OneRF system as the facial pain market sees projected growth to $416 million by 2030.- benzinga.com NeuroOne Issues Letter To Shareholders; Reiterating FY25 Guidance, With Product Revenues Expected To Increase To Between $8M-$10M, Representing An Increase Of Between 132% To 190% When Compared To Product Revenue Of $3.5M In FY24 Today, we stand as a larger, more mature company than ever before as we ramp revenues and product margins. We have a world class strategic partner, the necessary capital to execute on our strategic…
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com Nasdaq Dips 5%; NeuroOne Medical Technologies Shares Plummet 
benzinga.com Dow Tumbles 1,100 Points; US Economy Adds 228,000 Jobs In March - benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com Guess, Simulations Plus And 3 Stocks To Watch Heading Into Friday - benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com Neuroone Medical Technologies Commences A Proposed Underwritten Registered Public Offering Of Shares Of Its Common Stock NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) (the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological…
- benzinga.com NeuroOne Medical Tech Affirms FY2025 Sales Guidance of $8.00M-$10.00M NeuroOne Medical Tech (NASDAQ:NMTC) affirms FY2025 sales outlook from $8.00 million-$10.00 million to $8.00 million-$10.00 million.
benzinga.com NeuroOne Medical Tech Q1 EPS $0.06 Up From $(0.14) YoY, Sales $3.27M Up From $977.65K YoY NeuroOne Medical Tech (NASDAQ:NMTC) reported quarterly earnings of $0.06 per share. This is a 142.86 percent increase over losses of $(0.14) per share from the same period last year. The company…- benzinga.com Earnings Scheduled For February 12, 2025
- benzinga.com NeuroOne Regains Compliance with Nasdaq Listing Requirements NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from…